Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Clare Oni"'
Autor:
Thompson Olaoni, Chandan Saha, Claire N. Harrison, Monika Ciesielska, Yurina Miki, Priya Sriskandarajah, Jennifer O'Sullivan, Chienye Asinobi, Deepti Radia, Donal P. McLornan, Clare Oni, Claire Woodley, Rebecca Todd, Anna Green, Mark Ong, Susan Asirvatham, Clive Grattan, Natalia Curto-Garcia
Publikováno v:
Blood. 138:3625-3625
Background: Systemic mastocytosis (SM) is a disorder of neoplastic mast cells ranging from indolent to aggressive multi-system disease. We previously reported our large single centre experience managing SM. Since 2019 patients have had access to new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c744c96472b6304d4d66fe1acfa9b4c7
https://doi.org/10.1182/blood-2021-152234
https://doi.org/10.1182/blood-2021-152234
Publikováno v:
British journal of haematologyReferences. 188(5)
Mastocytosis is a rare disease with varied presentation, myriad symptomatology and variable prognosis. Most patients present with cutaneous disease and mediator-related symptomatology with a small subset having systemic disease (systemic mastocytosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff8de33867e0eb29d430e14938c64e22
https://pubmed.ncbi.nlm.nih.gov/31985050
https://pubmed.ncbi.nlm.nih.gov/31985050
Autor:
Deimante Drasutyte, Nicholas C.P. Cross, Natalia Curto-Garcia, Joana M. P. Desterro, Clive Grattan, Mark Ong, Clare Oni, Miki Yurina, Yvonne Francis, Jennifer O'Sullivan, Thompson Olaoni, Donal P. McLornan, Mufaddal Moonim, Anna Green, Claire Woodley, Monika Ciesielska, Deepti Radia
Publikováno v:
Blood. 134:2960-2960
Introduction: Systemic mastocytosis (SM) is a heterogeneous disorder of neoplastic mast cells ranging from an indolent to aggressive multi-system disease. We registered our UK Mastocytosis Centre of Excellence with the European Competence Network of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efbb361973895766db31c51924a7675f
https://doi.org/10.1182/blood-2019-130477
https://doi.org/10.1182/blood-2019-130477
Autor:
Saaeha Rauz, Adrian Jones, Ben Fisher, Wan-Fai Ng, Costantino Pitzalis, Ian Giles, Peter Lanyon, Simon J. Bowman, John McLaren, David Coady, Clare Oni, Paul Emery, Sheryl Mitchell, John Hunter, N Gendi, Mohammed Akil, Victoria Hindmarsh, Neil McHugh, Robert J. Moots, Nurhan Sutcliffe, Vadivelu Saravanan, Elizabeth Price, Michele Bombardieri, Annie Cooper, David A. Isenberg, Marian Regan, Bhaskar Dasgupta, Katherine James, Steven Young-Min, Francesca Barone, Monica Gupta, Bridget Griffiths, Andrea Richards, Colin T. Pease
Publikováno v:
Oni, C, Mitchell, S, James, K, Ng, W-F, Griffiths, B, Hindmarsh, V, Price, E, Pease, C T, Emery, P, Lanyon, P, Jones, A, Bombardieri, M, Sutcliffe, N, Pitzalis, C, Hunter, J, Gupta, M, McLaren, J, Cooper, A, Regan, M, Giles, I, Isenberg, D, Saravanan, V, Coady, D, Dasgupta, B, McHugh, N, Young-Min, S, Moots, R, Gendi, N, Akil, M, Barone, F, Fisher, B, Rauz, S, Richards, A, Bowman, S J 2016, ' Eligibility for clinical trials in primary Sjögren's syndrome : lessons from the UK Primary Sjögren's Syndrome Registry ', Rheumatology, vol. 55, no. 3, pp. 544-552 . https://doi.org/10.1093/rheumatology/kev373
OBJECTIVE: To identify numbers of participants in the UK Primary Sjögren's Syndrome Registry (UKPSSR) who would fulfil eligibility criteria for previous/current or potential clinical trials in primary SS (pSS) in order to optimize recruitment.METHOD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d630f5d164d159b1b93b2a002750e29
https://doi.org/10.1093/rheumatology/kev373
https://doi.org/10.1093/rheumatology/kev373